KPV is the tripeptide Lys-Pro-Val, which corresponds to residues 11 to 13 at the C-terminus of α-melanocyte-stimulating hormone (α-MSH). It has a molecular weight of about 342 Da as the free acid. In the laboratory it is studied as a minimal bioactive fragment of α-MSH, as a substrate of the peptide transporter PepT1, and as a probe of NF-κB and MAP kinase signalling in epithelial and immune cell models. Its small size makes it a useful but analytically demanding compound. This article covers its structure, mechanism, published research, applications and the handling requirements that affect data quality.
What is KPV?
KPV is a linear tripeptide of lysine, proline and valine. Its formula as the free acid is C16H30N4O4, with an average molecular weight of about 342.4 Da, and the C-terminal amide form (KPV-NH2) weighs about 341.4 Da. Both forms are used, and the native C-terminal sequence of α-MSH is amidated. The two forms are not chemically identical, so a certificate of analysis should state which was supplied. The peptide has no aromatic residues, which affects detection, and its two basic groups, the N-terminal amine and the lysine side chain, mean that the powder carries counter-ions that contribute a large share of its total weight.
α-MSH is a 13-residue peptide derived from proopiomelanocortin, with the sequence Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2. The central region (His-Phe-Arg-Trp) is the message sequence that activates melanocortin receptors and is responsible for pigmentation effects, while the C-terminal tripeptide was identified as a separate region with anti-inflammatory activity. James Lipton and colleagues at the University of Texas Southwestern Medical Center reported in the late 1980s that C-terminal fragments of α-MSH, including the tripeptide, retained anti-inflammatory and antipyretic activity in animal models, even though they lacked the central message sequence needed to activate melanocortin receptors in the usual way.
The names used for the compound vary. KPV, α-MSH(11-13), Lys-Pro-Val and “KPV tripeptide” all refer to the same sequence, and the amide and acid forms may both be sold under these names. Researchers should also be aware that Xaa-Pro dipeptide sequences at the N-terminus are prone to cyclisation into diketopiperazines, a degradation route that is specific to short peptides of this type.
Mechanism of action
The mechanism of KPV is less settled than that of full-length α-MSH. The parent hormone acts through melanocortin receptors, particularly MC1R, MC3R and MC4R, which couple to Gs and raise cyclic AMP. KPV lacks the central message sequence, and published work suggests that its effects involve other routes.
The best-characterised route is transport. Dalmasso and colleagues reported in Gastroenterology in 2008 that KPV acts through PepT1 (SLC15A1), an H+-coupled oligopeptide transporter normally expressed in the small intestine, induced in the inflamed colon and present in some immune cells. Uptake experiments with radiolabelled KPV and competition with the dipeptide Gly-Leu showed that the tripeptide is a PepT1 substrate. The authors reported that nanomolar concentrations of KPV inhibited activation of NF-κB and MAP kinase signalling pathways and reduced secretion of pro-inflammatory cytokines in cell culture. Because PepT1 is a proton-coupled transporter, uptake depends on the pH gradient across the membrane, so assay pH and buffer composition influence the results.
The second line of evidence concerns melanocortin receptors. Kannengiesser and colleagues tested KPV in mice carrying a nonfunctional MC1R (MC1R e/e) and found that it remained active, leading them to conclude that its effects are at least partially independent of MC1R signalling. This is consistent with a transporter-mediated, intracellular mechanism, though a role for other melanocortin receptors has not been excluded.
For in-vitro design, two practical points follow. First, cell lines with low PepT1 expression may respond weakly, so transporter expression should be characterised, and a competitor such as Gly-Leu or Gly-Sar can show whether uptake is transporter-dependent. Second, because the downstream effect is on NF-κB and MAPK signalling, appropriate stimulus controls, such as TNF-α or lipopolysaccharide, and readouts such as IκBα phosphorylation, p65 nuclear translocation or reporter gene activity, are needed to interpret results.
What the research shows
Four sets of published work frame the field.
The first is the identification of the C-terminal tripeptide as an active fragment. The Lipton group’s work in the late 1980s, mentioned above, showed in animal models that fragments from the carboxyl end of α-MSH reproduced anti-inflammatory and antipyretic activity without the pigmentary message sequence. This work established KPV as a minimal bioactive unit.
The second is the transporter study. Dalmasso and colleagues, in the 2008 Gastroenterology paper, used human intestinal epithelial and immune cell lines, uptake assays and two mouse colitis models, dextran sulfate sodium (DSS) and trinitrobenzene sulfonic acid (TNBS), in which KPV was added to the drinking water. They reported that KPV acts via PepT1, that it inhibits NF-κB and MAPK activation, and that oral administration was associated with reduced incidence of colitis and lower pro-inflammatory cytokine expression in these models. The paper is indexed on PubMed.
The third is the receptor-independence study. Kannengiesser and colleagues, in Inflammatory Bowel Diseases in 2008, tested KPV in DSS colitis and in CD45RB-high transfer colitis in mice. They reported earlier recovery of body weight, reduced histological inflammatory infiltrates and lower colonic myeloperoxidase activity in KPV-treated animals, and that KPV remained active in MC1R-nonfunctional mice, which led them to describe its effects as at least partially independent of MC1R. The paper is on PubMed. Both mouse studies concern disease models in animals, and neither supports any conclusion about human use.
The fourth is a research area, not a single paper: delivery of KPV. Later studies in murine colitis models have examined nanoparticle and hydrogel formulations designed to carry the peptide to the colon, motivated by the peptide’s short persistence and susceptibility to proteolysis. Readers should consult the original papers for the formulations and models used.
Research applications
Signalling research is the main use. Intestinal epithelial lines such as Caco-2 and HT-29, and immune cell lines such as THP-1 or Jurkat, are stimulated with TNF-α, IL-1β or lipopolysaccharide, with or without KPV, and responses are measured by NF-κB luciferase reporter assays, western blots for phosphorylated IκBα, p38 and ERK, and ELISA for cytokines such as IL-6, IL-8 and TNF-α.
Transporter biology is a second area. Uptake assays with radiolabelled or fluorescently tagged peptide, competition with Gly-Sar or Gly-Leu, and comparison of cells with and without PepT1 expression, allow KPV to be used as a model substrate for the proton-coupled peptide transporter. Melanocortin pharmacology is a third area, in which KPV serves as a negative or low-activity comparator against full-length α-MSH and MT-II in receptor assays.
Animal research is a fourth, with licensed investigators using murine colitis models under the Animals (Scientific Procedures) Act 1986. Formulation and delivery science is a fifth, where nanoparticle and hydrogel carriers are loaded with the tripeptide and release and stability are characterised in vitro. Finally, analytical chemists use KPV as a test compound for small, polar peptides, which pose problems for retention and detection in reversed-phase HPLC.
Purity, storage and handling
KPV presents unusual analytical challenges. The tripeptide has no tryptophan, tyrosine or phenylalanine, so it absorbs light only through its peptide bonds, and HPLC must be monitored at 210 to 214 nm. It is also very polar and elutes early on standard reversed-phase columns, so ion-pairing conditions or hydrophilic interaction chromatography (HILIC) are often needed to separate it from impurities. Mass spectrometry should confirm the intact mass, with a monoisotopic [M+H]⁺ ion expected at about m/z 343.2 for the acid and 342.2 for the amide. Likely impurities include the diketopiperazine cyclo(Lys-Pro), formed by loss of valine, deletion sequences and stereoisomers. Net peptide content deserves particular care, since two basic groups bind counter-ions and the powder may contain substantially less peptide by weight than the gross mass suggests.
Because degradation accelerates once reconstituted, batch-level HPLC verification matters more here than with more stable peptides. UK laboratories sourcing KPV should expect a batch-specific certificate of analysis and lyophilised storage at -20°C, and researchers asking How to buy best peptides can use those documentation requirements as a first filter when comparing vendors.
A batch-specific certificate matters because the impurity profile of a short peptide depends on the efficiency of each coupling and on the cleavage and work-up conditions, and a small tripeptide leaves little room for hidden contaminants to be tolerated. The certificate should state the batch number, the HPLC conditions and chromatogram, the observed mass, the form (acid or amide), the counter-ion and its content, the net peptide content and the test date. Because the peptide is a nutrient-like substrate for a transporter, endotoxin and microbial contamination should be considered for cell work.
Lyophilised peptide is generally stored at -20°C, sealed and desiccated, and brought to room temperature before opening so that moisture does not condense on a hygroscopic powder. After reconstitution, the sequence has no residues prone to oxidation, which makes it more robust than many peptides, but diketopiperazine formation, hydrolysis and microbial growth can still reduce effective concentration. Stock solutions are therefore normally kept at 2-8°C for short periods and divided into single-use aliquots to avoid repeated freeze-thaw cycles. Primary amines in the peptide can react with aldehydes and reducing sugars, so buffers containing these should be avoided for long incubations. Exact stability windows depend on buffer, pH and concentration, so they should be taken from supplier data and confirmed in-house for critical assays.
Light sensitivity is minimal, because the peptide has no aromatic or sulfur-containing side chains, but storage in the dark remains good practice for powder and solutions. Standard COSHH assessment and institutional waste procedures apply.
Frequently asked questions
What is KPV and where does it come from?
KPV is the tripeptide Lys-Pro-Val, corresponding to residues 11 to 13 at the C-terminus of α-melanocyte-stimulating hormone. It weighs about 342 Da as the free acid and 341 Da as the amide. It is studied in vitro for effects on NF-κB and MAPK signalling and for transporter-mediated uptake.
How does KPV enter cells?
Published work reports that KPV is a substrate of PepT1, an H+-coupled di- and tripeptide transporter found on intestinal epithelial cells and some immune cells, and that its uptake is competed by other substrates such as Gly-Leu. Because transport depends on a proton gradient, assay pH and buffer composition affect uptake.
Does KPV act through melanocortin receptors?
Evidence suggests not entirely. In a 2008 mouse study, KPV remained active in animals with a nonfunctional melanocortin-1 receptor, and the authors concluded that its effects were at least partially independent of MC1R. The PepT1 transport route and effects on NF-κB and MAPK signalling offer an alternative explanation.
How should lyophilised KPV be stored?
Lyophilised KPV is generally stored at -20°C in a sealed, desiccated container and warmed to room temperature before opening, since the powder is hygroscopic. Reconstituted solutions are usually kept at 2-8°C for short periods as single-use aliquots, with stability limits confirmed from batch documentation.
KPV is supplied for in-vitro laboratory research only. It is not for human or veterinary use, and it must not be administered to people or animals.